Cargando…

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells

Development of targeted therapies for triple-negative breast cancer (TNBC) is an unmet medical need. Cisplatin has demonstrated its promising potential for the treatment of TNBC in clinical trials; however, cisplatin treatment is associated with hypoxia that, in turn, promotes cancer stem cell (CSC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sulaiman, Andrew, McGarry, Sarah, Chambers, Jason, Al-Kadi, Emil, Phan, Alexandra, Li, Li, Mediratta, Karan, Dimitroulakos, Jim, Addison, Christina, Li, Xuguang, Wang, Lisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461107/ https://www.ncbi.nlm.nih.gov/pubmed/32806648 http://dx.doi.org/10.3390/ijms21165788

Ejemplares similares

Dual inhibition of Wnt and Yes‐associated protein signaling retards the growth of triple‐negative breast cancer in both mesenchymal and epithelial states
por: Sulaiman, Andrew, et al.
Publicado: (2018)

Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
por: Sulaiman, Andrew, et al.
Publicado: (2018)

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
por: Sulaiman, Andrew, et al.
Publicado: (2021)

At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy
por: Sulaiman, Andrew, et al.
Publicado: (2022)

Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination
por: St Germain, Carly, et al.
Publicado: (2010)

CSCs in Breast Cancer—One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs
por: Sulaiman, Andrew, et al.
Publicado: (2019)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity
por: Sarnella, Annachiara, et al.
Publicado: (2020)

Hypoxia‐Induced FUS–circTBC1D14 Stress Granules Promote Autophagy in TNBC
por: Liu, Ying, et al.
Publicado: (2023)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC
por: Wu, Xiaoqing, et al.
Publicado: (2023)

A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
por: El-Sahli, Sara, et al.
Publicado: (2021)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels
por: Honeywell, D. Rice, et al.
Publicado: (2013)

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
por: Guan, Xiaolin, et al.
Publicado: (2022)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Hypoxia‐induced YAP activation and focal adhesion turnover to promote cell migration in mesenchymal TNBC cells
por: Nguyen, Thi My Hang, et al.
Publicado: (2023)

Pd(II) and Pt(II) Trinuclear Chelates with Spermidine: Selective Anticancer Activity towards TNBC-Sensitive and -Resistant to Cisplatin
por: Vojtek, Martin, et al.
Publicado: (2023)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
por: St-Denis-Bissonnette, Frederic, et al.
Publicado: (2022)

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells()()
por: Bar, Jair, et al.
Publicado: (2016)

Core promoter in TNBC is highly mutated with rich ethnic signature
por: Huang, Teng, et al.
Publicado: (2022)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells
por: Pradhan, Shrikant, et al.
Publicado: (2016)

1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel
por: Modi, Karan, et al.
Publicado: (2020)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
por: Estrada-Pérez, Alan Rubén, et al.
Publicado: (2022)

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC
por: Yi, Jiarong, et al.
Publicado: (2021)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3fvlvgq77pdavgfmm1s9ebemhg